Phase 1 Start
URGN: Phase 1 Start: A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacoki
September 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 30, 2026
- Company
- UroGen Pharma Ltd. (URGN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start~month
Phase 1 Start: A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacoki
- Company
- UroGen Pharma Ltd. (URGN)
- Indication
- Urothelial Carcinoma Bladder; Urothelial Carcinoma Recurrent; Bladder (Urothelial, Transitional Cell) Cancer